Jordi Sarto
Overview
Explore the profile of Jordi Sarto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Millan A, Lal-Trehan Estrada U, Falgas N, Guillen N, Borrego-Ecija S, Junca-Parella J, et al.
Eur Radiol
. 2025 Feb;
PMID: 39934339
Objectives: Frontotemporal dementia (FTD) usually shows more asymmetric atrophy patterns than Alzheimer's disease (AD). We aim to quantify this asymmetry to differentiate FTD, AD, and FTD subtypes. Methods: We studied...
2.
Naranjo L, Sarto J, Nos C, Alcolea D, Rodriguez-Baz I, Navalpotro-Gomez I, et al.
J Neurol
. 2025 Feb;
272(3):198.
PMID: 39932589
Discrepancies in results between cerebrospinal fluid (CSF) 14-3-3 protein and prion protein detection using real-time quaking-induced conversion (RT-QuIC) might limit the confidence in ante-mortem clinical diagnosis of sporadic Creutzfeldt-Jakob disease...
3.
Sarto J, Esteller-Gauxax D, Guillen N, Falgas N, Borrego-Ecija S, Massons M, et al.
J Neurol
. 2025 Jan;
272(2):160.
PMID: 39849125
Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have...
4.
Perez-Millan A, Thirion B, Falgas N, Borrego-Ecija S, Bosch B, Junca-Parella J, et al.
Neurobiol Aging
. 2024 Sep;
144:1-11.
PMID: 39232438
Neuroimaging and fluid biomarkers are used to differentiate frontotemporal dementia (FTD) from Alzheimer's disease (AD). We implemented a machine learning algorithm that provides individual probabilistic scores based on magnetic resonance...
5.
Falgas N, Pena-Gonzalez M, Val-Guardiola A, Perez-Millan A, Guillen N, Sarto J, et al.
Alzheimers Dement
. 2024 Jul;
20(9):6351-6364.
PMID: 39051173
Introduction: Early-onset Alzheimer's disease (EOAD) shows a higher burden of neuropsychiatric symptoms than late-onset Alzheimer's disease (LOAD). We aim to determine the differences in the severity of neuropsychiatric symptoms and...
6.
Guillen N, Perez-Millan A, Falgas N, Lledo-Ibanez G, Rami L, Sarto J, et al.
Sci Rep
. 2024 Jun;
14(1):12927.
PMID: 38839833
We aimed to characterize the cognitive profile of post-acute COVID-19 syndrome (PACS) patients with cognitive complaints, exploring the influence of biological and psychological factors. Participants with confirmed SARS-CoV-2 infection and...
7.
Sarto J, Esteller-Gauxax D, Tort-Merino A, Guillen N, Perez-Millan A, Falgas N, et al.
J Neurol
. 2023 Dec;
271(4):1973-1984.
PMID: 38151575
Plasma biomarkers have emerged as promising tools for identifying amyloid beta (Aβ) pathology. Before implementation in routine clinical practice, confounding factors modifying their concentration beyond neurodegenerative diseases should be identified....
8.
Perez-Carbonell L, Sarto J, Gaig C, Munoz-Lopetegi A, Ruiz-Garcia R, Naranjo L, et al.
Sleep Med
. 2023 Jun;
108:11-15.
PMID: 37302168
Background: Gerstmann-Sträussler-Scheinker (GSS) is a rare prion disease with heterogeneous clinical presentation. Although sleep-related abnormalities are prominent and well-known in other prion diseases such as fatal familial insomnia and Creutzfeldt-Jakob...
9.
Forno G, Contador J, Perez-Millan A, Guillen N, Falgas N, Sarto J, et al.
Eur J Neurol
. 2022 Dec;
30(3):597-605.
PMID: 36463489
Background And Purpose: How the APOE genotype can differentially affect cortical and subcortical memory structures in biomarker-confirmed early-onset (EOAD) and late-onset (LOAD) Alzheimer's disease (AD) was assessed. Method: Eighty-seven cerebrospinal...
10.
Sarto J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, Falgas N, Esteller D, et al.
Neurology
. 2022 Nov;
100(8):e860-e873.
PMID: 36450604
Background And Objectives: Blood-based biomarkers have emerged as minimally invasive options for evaluating cognitive impairment. Most studies to date have assessed them in research cohorts, limiting their generalization to everyday...